Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
MDxHealth ( (MDXH) ) has issued an update.
On May 14, 2025, MDxHealth SA released its financial results for the first quarter ending March 31, 2025. The company reported a revenue increase to $24.3 million from $19.8 million in the same period the previous year. Despite the revenue growth, the company experienced a loss of $9.2 million, slightly higher than the $8.5 million loss in the first quarter of 2024. The financial results indicate ongoing challenges in managing costs and achieving profitability, impacting the company’s financial stability and market positioning.
The most recent analyst rating on (MDXH) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on MDxHealth stock, see the MDXH Stock Forecast page.
Spark’s Take on MDXH Stock
According to Spark, TipRanks’ AI Analyst, MDXH is a Neutral.
MDxHealth’s strong revenue growth and positive technical momentum are offset by financial instability and valuation concerns. The optimistic outlook from the earnings call strengthens the score, yet high leverage and negative profitability weigh heavily.
To see Spark’s full report on MDXH stock, click here.
More about MDxHealth
MDxHealth SA is a company based in Herstal, Belgium, operating in the healthcare industry. It specializes in molecular diagnostics, focusing on the development and commercialization of advanced epigenetic and other molecular tests for cancer assessment and management.
Average Trading Volume: 78,635
Technical Sentiment Signal: Strong Sell
Current Market Cap: $90.58M
Learn more about MDXH stock on TipRanks’ Stock Analysis page.